Genentech Reports Results of Tecentriq in P-III IMpower010 Study for 1L Treatment of NSCLC

 Genentech Reports Results of Tecentriq in P-III IMpower010 Study for 1L Treatment of NSCLC

Genentech Reports Results of Tecentriq in P-III IMpower010 Study for 1L Treatment of NSCLC

Shots:

  • The P-III IMpower010 involves assessing Tecentriq + BSC in 1,005 participants in a ratio (1:1) with Stage IB-IIIA NSCLC, following surgical resection and up to 4 cycles of adjuvant cisplatin-based CT
  • Results: 34% reduction in risk of death in people with Stage II-IIIA NSCLC. In the larger population of all randomized Stage II-IIIA study patients showed a 21% reduction in risk of disease recurrence or death after a median follow-up of 32.2mos, DFS (42.3mos. vs 35.3mos.), no new safety signals were observed
  • Tecentriq is the first and only cancer immunotherapy to show positive P-III results in the adjuvant lung cancer setting

Click here to­ read full press release/ article | Ref: Businesswire | Image: Center for Health Journalism

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post